March 20, 2014 | Israeli biotech startup Gamida Cell, which develops stem-cell based therapies, is reportedly in advanced acquisition talks at a company value of $600 million. The Times of Israel reports that the company has received a large buy-out offer from an international pharmaceutical company.
Related posts
Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023
Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023
Israel Opens Its First Satellite Observatory
February 02, 2023
Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments